Arcturus is a giant star with a relatively cool surface temperature of 4300 kelvins (7300° Fahrenheit). Spica also is a giant, but it’s among the hottest of stars. Its surface burns at 20,000 K ...

Arcturus’ pipeline is rich with promising candidates across various stages of development. The company’s cystic fibrosis (CF) program, ARCT-032, has entered Phase 2 clinical trials, with ...

Instead, the title belongs to Regulus Arcturus Black, who more than deserves to be called a hero despite never meeting Harry. Though he is dead long before the series begins, Regulus played a part ...

Analysts have recently evaluated Arcturus Therapeutics and provided 12-month price targets. The average target is $61.43, accompanied by a high estimate of $68.00 and a low estimate of $50.00.

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be acquired by Novartis. 1 This will add the potential kidney disease treatment ...

Novartis NOVN 0.23 % increase; green up pointing triangle has agreed to acquire Regulus Therapeutics RGLS 0.38 % increase; green up pointing triangle for a total equity value of up to roughly $1.7 ...

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today ...